Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer: A Phase II Brown University Oncology Group Research Project

NCT01650350 is registered in ClinicalTrials.gov with Brown University as lead sponsor.

NCT NCT01650350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01650350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer: A Phase II Brown University Oncology Group Research Project
Lead sponsor
Brown University
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2012
Completion date
October 31, 2013
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, prostate cancer, renal cancer